Keyserling H, Papa T, Koranyi K, et al. Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents. Arch Pediatr Adolesc Med. 2005;159(10):907-913.
Granoff DM, Harrison LH, Borrow R. Meningococcal vaccines. In: Plotkin SA, Orenstein WA, eds.Vaccines. 5th ed. Philadelphia, PA: WB Saunders Co.; 2008.
CDC. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2007;54(RR-7):1-21.
Erickson LJ, De Wals P, McMahon J, Heim S. Complications of meningococcal disease in college students. Clin Infect Dis. 2001;33(5):737-739.
Warren HS Jr, Gonazalez RG, Tian Di. Case records of the Massachusetts General Hospital. Case 38-2003: A 12-year-old girl with fever and coma. N Engl J Med. 2003;349(24):2341-2349.
CDC. Recommended immunization schedules for persons aged 0-18 years — United State, 2008. MMWR. 2008;57(1):Q1-Q4.
CDC. Update: Guillain-Barré syndrome among recipients of Menactra® meningococcal conjugate vaccine — United States, June 2005-September 2006. MMWR. 2006;55(41):1120-1124.
Harrison LH, Pass MA, Mendelsohn AB, et al. Invasive meningococcal disease in adolescents and young adults. JAMA. 2001;286(6):694-699.
CDC. Summary of notifiable diseases — United States, 2004. MMWR. 2004;53(53):1-81.
CDC. Summary of notifiable diseases — United States, 2005. MMWR. 2005;54(53):1-92.
CDC. Summary of notifiable diseases — United States, 2006. MMWR. 2006;55(53):1-94.
CDC. Revised recommendations of the Advisory Committee on Immunization Practices to vaccinate all persons aged 11-18 years with meningococcal conjucate vaccine. MMWR. 2007;56(31):794-795.
Shoham S, Cover C, Donegan N, Fulnecky E, Kumar P. Cyrptococcus neoformans meningitis at 2 hospitals in Washington, D.C.: adherence of health care providers to published practice guidelines for the management of cryptococcal disease. Clin Infect Dis. 2005;40(3):477-479.
Office of Epidemiology & Disease Control Programs. Maryland Department of Health & Mental Hygiene; Meningococcal disease update. http://edcp.org/html/meningupdate.html. Accessed March 7, 2008.
Commonwealth of Massachusetts. Chapter 229 of the acts of 2004. An act requiring college students immunization against meningococcal disease. http://www.mass.gov/legis/laws/seslaw04/sl040229.htm. Accessed March 7, 2008.
Indication
Menactra vaccine is given to persons 2 through 55 years of age for active immunization against invasive meningococcal disease caused by N meningitidis serogroups A, C, Y, and W-135. Menactra vaccine will not stimulate protection against infection caused by N meningitidis other than serogroups A, C, Y, and W-135.
Safety Information
Side effects to Menactra vaccine include injection site pain, redness, and swelling; headache or fatigue. Other side effects may occur. Vaccination should be avoided by persons with known hypersensitivity (severe allergic reaction) to any ingredient of the vaccine, including latex (which is used in the vial stopper), or by any persons previously diagnosed with Guillain-Barré syndrome. There is a potential for an increased chance of getting Guillain-Barré syndrome following vaccination. Vaccination with Menactra vaccine may not protect all individuals.
For more information about Menactra vaccine, talk to your health-care professional.